PIK3CB and neoplasm: The aberrant PI3K-Akt signaling in tumor cells is attributed to the platinum-resistant phenotype, and the combination of cisplatin and LY-294002 (a PI3K-Akt dual kinase inhibitor) was found to prevent 3D spheroid formation and sensitize cells to cisplatin [110].